Shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX – Get Rating) traded down 4.6% during trading on Wednesday . The stock traded as low as $5.95 and last traded at $6.03. 101,680 shares changed hands during trading, a decline of 44% from the average session volume of 181,220 shares. The stock had previously closed at $6.32.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of BriaCell Therapeutics in a report on Friday, February 24th.
BriaCell Therapeutics Stock Performance
The firm has a market cap of $91.09 million, a PE ratio of -2.79 and a beta of 1.23. The company’s 50-day simple moving average is $6.93 and its two-hundred day simple moving average is $6.49.
Institutional Investors Weigh In On BriaCell Therapeutics
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company, which engages in the development of immunotherapies for treatment of cancer. Its technologies include Bria-IMT and Bria-OTS. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
- Get a free copy of the StockNews.com research report on BriaCell Therapeutics (BCTX)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.